BR9912684A - Composto de fórmula (i), composição farmacêutica compreendendo o composto, método, processo e seu uso - Google Patents

Composto de fórmula (i), composição farmacêutica compreendendo o composto, método, processo e seu uso

Info

Publication number
BR9912684A
BR9912684A BR9912684-2A BR9912684A BR9912684A BR 9912684 A BR9912684 A BR 9912684A BR 9912684 A BR9912684 A BR 9912684A BR 9912684 A BR9912684 A BR 9912684A
Authority
BR
Brazil
Prior art keywords
hydroxy
compound
optionally substituted
formula
protected
Prior art date
Application number
BR9912684-2A
Other languages
English (en)
Inventor
Tadashi Terasaka
Katsuya Nakamura
Nobuo Seki
Masako Kuno
Susumu Tsujimoto
Akihiro Sato
Isao Nakanishi
Takayoshi Kinoshita
Nobuya Nishio
Hiroyuki Okumura
Kiyoshi Tsuji
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP4840A external-priority patent/AUPP484098A0/en
Priority claimed from AUPP7355A external-priority patent/AUPP735598A0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of BR9912684A publication Critical patent/BR9912684A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"COMPOSTO DE FóRMULA (I), COMPOSIçãO FARMACêUTICA COMPREENDENDO O COMPOSTO, MéTODO, PROCESSO E SEU USO." Compostos de imidazol tendo atividade inibidora de adenosina desaminase representados pela seguinte fórmula: onde R¹ é hidrogênio, hidroxi, hidroxi protegido, ou arila opcionalmente substituído com substituinte(s) adequado(s); R² é hidrogênio ou alquila inferior; R³ é hidroxi ou hidroxi protegido; R^ 4^ é ciano, (hidroxi)iminoamino alquila (inferior), carboxi, carboxi protegido, grupo heterocíclico opcionalmente substituído com amino ou carbamoíla opcionalmente substituído com substituinte(s) adequado(s); e - A - é - Q - ou -O-Q-, onde Q ligação simples ou alquileno inferior; contanto que quando R² for alquila inferior, então R¹ é hidroxi, hidroxi protegido ou arila opcionalmente substituído com substituinte(s) adequado(s), seu profármaco ou seu sal. Os compostos são úteis no tratamento e/ou prevenção de doenças para as quais a adenosina é eficaz.
BR9912684-2A 1998-07-23 1999-07-22 Composto de fórmula (i), composição farmacêutica compreendendo o composto, método, processo e seu uso BR9912684A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP4840A AUPP484098A0 (en) 1998-07-23 1998-07-23 Novel imidazole compounds
AUPP7355A AUPP735598A0 (en) 1998-11-27 1998-11-27 Novel imidazole compounds
PCT/JP1999/003939 WO2000005217A1 (en) 1998-07-23 1999-07-22 Imidazole compounds and their use as adenosine deaminase inhibitors

Publications (1)

Publication Number Publication Date
BR9912684A true BR9912684A (pt) 2001-05-02

Family

ID=25645831

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912684-2A BR9912684A (pt) 1998-07-23 1999-07-22 Composto de fórmula (i), composição farmacêutica compreendendo o composto, método, processo e seu uso

Country Status (16)

Country Link
US (1) US6359145B1 (pt)
EP (1) EP1098885B9 (pt)
JP (1) JP4525883B2 (pt)
KR (1) KR100429754B1 (pt)
CN (1) CN1291979C (pt)
AT (1) ATE282599T1 (pt)
BR (1) BR9912684A (pt)
CA (1) CA2338305A1 (pt)
DE (1) DE69922009T2 (pt)
ES (1) ES2234269T3 (pt)
HK (1) HK1041264B (pt)
HU (1) HUP0103303A3 (pt)
MX (1) MXPA01000549A (pt)
PT (1) PT1098885E (pt)
RU (1) RU2243220C2 (pt)
WO (1) WO2000005217A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP921299A0 (en) 1999-03-15 1999-04-15 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
US6103702A (en) * 1999-05-24 2000-08-15 Board Of Trustees Of The University Of Illinois Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome
AUPQ515700A0 (en) * 2000-01-19 2000-02-10 Fujisawa Pharmaceutical Co., Ltd. Imidazole compounds
AUPR636301A0 (en) 2001-07-13 2001-08-02 Fujisawa Pharmaceutical Co., Ltd. Imidazole compounds
AUPS058102A0 (en) * 2002-02-15 2002-03-14 Fujisawa Pharmaceutical Co., Ltd. Imidazole compounds
US20040175804A1 (en) * 2003-03-04 2004-09-09 Skonezny Paul M. Process for preparing dideoxyinosine using adenosine deaminase enzyme
TW200815388A (en) * 2006-04-18 2008-04-01 Wyeth Corp Chromane and chromene derivatives and uses thereof
US8314136B1 (en) 2006-05-23 2012-11-20 MedDEV, Inc. Method for treatment of alzheimer's disease and autism spectrum disorders
US7666893B2 (en) * 2006-05-23 2010-02-23 Meddev Inc. Method for treatment of neurodegenerative disorders
CN101679293A (zh) * 2007-06-11 2010-03-24 瓦莱塔健康私人有限公司 具有治疗免疫相关性和炎症性疾病作用的尿刊酸衍生物
JP5454458B2 (ja) * 2010-11-25 2014-03-26 信越化学工業株式会社 ポジ型レジスト材料及びパターン形成方法
CN108318594A (zh) * 2018-01-12 2018-07-24 上海中医药大学 一种液相色谱串联质谱法测定腺苷脱氨酶活性及筛选其抑制剂的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906965D0 (en) * 1989-03-28 1989-05-10 Schering Agrochemicals Ltd Fungicides
EP0653421B1 (en) * 1993-11-12 1997-01-15 Ishihara Sangyo Kaisha Ltd. Process for preparing 2-cyanoimidazole compounds
CA2261591A1 (en) * 1996-07-15 1998-01-22 Elie Abushanab Adenosine deaminase inhibitors

Also Published As

Publication number Publication date
CN1291979C (zh) 2006-12-27
CA2338305A1 (en) 2000-02-03
EP1098885B1 (en) 2004-11-17
RU2243220C2 (ru) 2004-12-27
HUP0103303A3 (en) 2002-09-30
WO2000005217A1 (en) 2000-02-03
HK1041264A1 (en) 2002-07-05
HK1041264B (zh) 2007-08-17
US6359145B1 (en) 2002-03-19
ATE282599T1 (de) 2004-12-15
KR100429754B1 (ko) 2004-05-03
DE69922009D1 (de) 2004-12-23
CN1319095A (zh) 2001-10-24
JP2002521369A (ja) 2002-07-16
HUP0103303A2 (hu) 2002-04-29
ES2234269T3 (es) 2005-06-16
EP1098885B9 (en) 2005-05-18
JP4525883B2 (ja) 2010-08-18
PT1098885E (pt) 2005-01-31
EP1098885A1 (en) 2001-05-16
KR20010072037A (ko) 2001-07-31
DE69922009T2 (de) 2005-04-07
MXPA01000549A (es) 2002-04-08

Similar Documents

Publication Publication Date Title
BR0313743A (pt) Benzimidazol quinolinonas e usos destas
BR0014136A (pt) Composto, uso do mesmo, métodos para a preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BR0014133A (pt) Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BR9909781A (pt) Composto de formula (i), processo para sua preparação, composição farmacêutica compreendendo dito composto, seu uso e método.
DE69425162D1 (de) 4,5-diaryloxazol-derivate
BR0014116A (pt) Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BR9916282A (pt) Composto, uso de um um composto e método de tratamento
BR0308146A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BR9912684A (pt) Composto de fórmula (i), composição farmacêutica compreendendo o composto, método, processo e seu uso
ZA967379B (en) Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid compounds and derivatives thereof.
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
BR0317183A (pt) Método de usar compostos de aminocianopiridina como inibidores de proteìna quinase-2 ativada por proteìna quinase ativada por mitógeno
IL114315A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same for inhibiting phosphodiesterase IV
TR199902203T2 (xx) Fernesil transferaz engelleyici, N-veya C-ba�lant�l� imidazoller ile ikame edilmi� 1,8-anele kinolinon t�revleri.
BR9914451A (pt) Composto de oxazol, processo para sua preparação, composição farmacêutica compreendendo dito composto, uso da composição e métodos de tratamento
ATE232531T1 (de) Heterobizyklische derivate
EA200500893A1 (ru) Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии
EA199800650A1 (ru) Новые соединения
BR0108816A (pt) Derivados de quinolina como antagonistas alfa-2
BR9916566A (pt) Complexo de inibidor de ras-farnesiltransferase esulfobutiléter-7-ß-ciclodextrina ou2-hidroxipropil-ß-ciclodextrina e processo
KR970015576A (ko) 신규 히디록시피리디논
NO984470L (no) Pyrrolopyrrolon-derivater som inhibitorer for neutrofil elastase
BRPI0407841A (pt) inibidores heterocìclicos de quinase
BR9712140A (pt) Agentes e processos para inibir a produção de citoquina, a adesão de cédulas e a produção de tnf - alfa e uso de um composto.
BR0114697A (pt) Derivados em ponte de piperazina

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP)

Free format text: TRANSFERIDO POR FUSAO DE: FUJISAWA PHARMACEUTICAL CO., LTD.

B25D Requested change of name of applicant approved

Owner name: ASTELLAS PHARMA INC. (JP)

Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA(S) 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 1986 DE 27/03/2009.